R. Coleman

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

A. Oza, J. Ledermann, E. Swisher, 2020 .

Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.

B. Monk, D. Cruickshank, M. Widschwendter, 2022, Gynecologic oncology.

184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer

I. Ray-Coquard, N. Concin, L. Mileshkin, 2021, Ovarian cancer.

Population exposure-safety and exposure-efficacy analyses for rucaparib in patients (pts) with recurrent ovarian carcinoma (rOC) from Study 10 and ARIEL2

A. Tinker, A. Oza, J. Brenton, 2020, Gynecologic Oncology.

ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

S. Lheureux, P. Zola, J. Sehouli, 2020, Gynecologic Oncology.